Miacalcic 100 IU/ml

Uses of Miacalcic: - Post menopausal osteoporosis - Paget's disease - Hypercalcemia Hypercalcaemia, Paget's disease of bone, Postmenopausal osteoporosis. Hypersensitivity.

Hormone in bone formation by Inhibiting bone resorption

Calcitonin is a polypeptide hormone produced by the ultimobranchial gland in non-mammalian vertebrates or by the mammalian thyroid parafollicular cells. It inhibits osteoclastic bone resorption and reduces bone turnover. It decreases tubular reabsorption and promotes renal excretion of Ca, Cl, Na, Mg, K and phosphate.

How to use Salmon Calcitonin: Use this medicine in the dose and duration as advised by your doctor. Check the label for directions before use. Insert the bottle tip into one nostril and close the other nostril. Direct the spray towards the sides of your nostril, away from the cartilage dividing the two sides of your nose. As you spray, breath gently and keep the head upright. Repeat the same process for the other nostrils. Adult Dose: Parenteral Hypercalcemia Initial dose: 4 IU/kg SC/IM q12hr May increase to 8 IU/kg SC/IM q12hr; may increase up to a maximum 8 IU/kg q6hr if unresponsive Paget Disease Initial dose: 100 IU SC/IM qDay Maintenance: 50 IU/day or 50-100 IU every 1-3 days Osteoporosis, Postmenopausal Indicated for the treatment of postmenopausal osteoporosis in women greater than 5 yr postmenopause 100 IU SC/IM every other day with calcium and vitamin D Nasal Spray: 1 spray (200 IU) qDay, alternate nostrils daily Child Dose: Safety and efficacy not established

Concurrent use w/ cardiac glycosides (e.g. digitalis) or Ca-channel blockers requires dosage adjustments of these drugs. May decrease serum concentration of lithium.

Hypersensitivity.

Common - Runny nose - Nasal irritation >10% Rhinitis (12%) 1-10% Arthralgia (4%),Back pain (5%),Expistaxis (4%),Injection site reactions (10%),Nausea (10%),Headache (3%),Flushing of face or hands (2-5%) <1% Abdominal pain,Possible allergic reactions,Appetite decreased,Edema of feet,Eye pain,Feverish sensation,Nausea,Nocturia,Possible local irritative effects in the respiratory tract,Salty taste Frequency Not Defined Tremors Potentially Fatal: Anaphylactic shock.

Pregnancy Category C. Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.

Precaution: Children <18 yr, renal impairment. Pregnancy, lactation. Serious hypersensitivity reactions, including fatal anaphylaxis, reported; consider skin testing prior to treatment. Hypocalcemia associated with tetany has been reported; ensure adequate intake of calcium and vitamin D Lactation: excretion in milk unknown/not recommended

Symptoms: Flushing, nausea, vomiting and dizziness. Management: Symptomatic and supportive treatment.

Store between 2-8° C.

Hormone in bone formation by Inhibiting bone resorption

It inhibits osteoclastic bone resorption and reduces bone turnover. It decreases tubular reabsorption and promotes renal excretion of Ca, Cl, Na, Mg, K and phosphate.

Pregnancy Category C. Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.